Evidence map›Paper›PMID 40978033›Full record

ArticleFrontiers in oncology2025

Successful CD19 chimeric antigen receptor T-cell therapy following autologous stem cell transplantation in a secondary central nervous system lymphoma patient with COVID-19 infection: a case report and literature review.

Xiaoning Wang, Juan Ren, Yuqi Wang, Minna Luo, Jing Li, Pengcheng He

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaoning Wang *Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Juan Ren *Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Yuqi Wang *Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Minna LuoDepartment of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Jing LiDepartment of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Pengcheng HeDepartment of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper reported a 64-year-old, secondary central nervous system lymphoma (sCNSL) patient with COVID-19 infection during CD19 chimeric antigen receptor T-cell (CAR-T) therapy following autologous stem cell transplantation (ASCT). Our findings demonstrate that the combination of ASCT and CAR-T for sCNSL may be feasible, even for SARS-CoV-2-positive immunocompromised lymphoma patients.

Indexed as

autologous stem cell transplantationCD19 chimeric antigen receptor T-cellCOVID-19diffuse large B-cell lymphomasecondary central nervous system lymphoma

Identifiers

PMID40978033
PMCPMC12446030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.